Lassen Ther­a­peu­tics reels in $85M Se­ries B for PhII test­ing in thy­roid eye dis­ease

Lassen Ther­a­peu­tics closed an over­sub­scribed $85 mil­lion Se­ries B on Tues­day morn­ing as the San Diego biotech brings its treat­ment can­di­date for thy­roid eye dis­ease in­to Phase II test­ing.

The Fra­zier Life Sci­ences-found­ed start­up is at­tempt­ing to go in­to a field with mul­ti­ple oth­er biotechs in clin­i­cal de­vel­op­ment, but Lassen hopes to carve out its own lane by ap­proach­ing the au­toim­mune dis­ease with a fi­bro-in­flam­ma­to­ry an­gle. Al­so known as TED, the dis­ease caus­es in­flam­ma­tion and some­times bulging in the eyes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER